Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) to Announce Fourth Quarter and Full-Year 2012 Financial Results and Corporate Update on March 7, 2013
Published: Feb 20, 2013
CAMBRIDGE, MA--(Marketwire - February 20, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report fourth quarter and full-year 2012 financial results before the NASDAQ Global Market opens on Thursday, March 7, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 34143150. Please specify to the operator that you would like to join the "Sarepta Fourth Quarter and Full-Year 2012 Earnings Call." The conference call will be webcast live under the events section of Sarepta's website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
Sarepta Investor Contact:
Sarepta Media Contact:
617.444.8424 ext 3124